DDrare: Database of Drug Development for Rare Diseases

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-FDG; 68Ga-FAPI; Abatacept; Afucosylated IgG1 kappa monoclonal antibody; Belimumab; Corticosteroids; Device: Mayo Interactive Breath Hold Monitor; Drug free, IS monotherapy and GC combined with IS; Extra blood draw samples; Glucocorticoids; INEBILIZUMAB; Inebilizumab; Leflunomide; Lenalidomide; MONITOR; Methionine; Mycophenolate; Mycophenolate mofetil; Perflubutane; Prednisolone; Prednisone; Prednisone and Belimumab; Prednisone and Mycophenolate mofetil; Procedure: biliary stent; Rilzabrutinib; Rituximab; T 614; Thalidomide; XMAB5871; XmAb5871; Zanubrutinib; Zanubrutinib 80 MG; [XmAb5871]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04520451 (ClinicalTrials.gov)	August 21, 2020	11/8/2020	Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients	An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease	IgG4-Related Disease	Drug: rilzabrutinib;Drug: Glucocorticoids	Principia Biopharma Inc.	Massachusetts General Hospital	Recruiting	18 Years	N/A	All	25	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04520451
(ClinicalTrials.gov)

August 21, 2020

11/8/2020

Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients

An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patients With IgG4-Related Disease

IgG4-Related Disease

Drug: rilzabrutinib;Drug: Glucocorticoids

Principia Biopharma Inc.

Massachusetts General Hospital

Recruiting

18 Years

N/A

All

Phase 2

United States